Intrinsic Value of S&P & Nasdaq Contact Us

Stryker Corporation SYK NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score
74/100
5/7 Pass
SharesGrow Intrinsic Value
$411.27
+18.9%
Analyst Price Target
$428.67
+23.9%

Stryker Corporation (SYK) generated $5.04B in operating cash flow for fiscal year 2025. After capital expenditures of $761M, free cash flow was $4.28B.

Free cash flow margin was 17.1% of revenue. Cash conversion ratio was 1.55x, indicating earnings are backed by cash.

The company returned $1.28B in dividends to shareholders during the period.

Criteria supported by this page:

  • HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (86/100, Pass) — $4.28B (17.1% FCF margin) supports a durable competitive advantage
  • INCOME (55/100) — Cash conversion ratio was 1.55x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 74/100 with 5/7 criteria passed.

SharesGrow 7-Criteria Score
74/100
SG Score
View full scorecard →
VALUE
32/100
Price-to-Earnings & upside
→ Valuation
FUTURE
79/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
83/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
86/100
Proven by this page
GROWTH
80/100
→ Income
~
INCOME
55/100
→ Income
Stryker Corporation Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $5.04B$5.04B$4.24B$3.71B$2.62B
Capital Expenditure $-761M$-761M$-755M$-575M$-588M
Free Cash Flow $4.28B$4.28B$3.49B$3.14B$2.04B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message